Literature DB >> 17957187

K(ATP) channel pharmacogenomics: from bench to bedside.

S Sattiraju1, S Reyes, G C Kane, A Terzic.   

Abstract

Inheritance plays a significant role in defining drug response and toxicity. Advances in molecular pharmacology and modern genomics emphasize genetic variation in dictating inter-individual pharmacokinetics and pharmacodynamics. A case in point is the homeostatic ATP-sensitive potassium (K(ATP)) channel, an established drug target that adjusts membrane excitability to match cellular energetic demand. There is an increased recognition that genetic variability of the K(ATP) channel impacts therapeutic decision-making in human disease.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17957187      PMCID： PMC2719888          DOI： 10.1038/sj.clpt.6100378

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


  35 in total

Review 1.  Hyperinsulinism in infancy: from basic science to clinical disease.

Authors:  Mark J Dunne; Karen E Cosgrove; Ruth M Shepherd; Albert Aynsley-Green; Keith J Lindley
Journal:  Physiol Rev       Date:  2004-01       Impact factor: 37.312

Review 2.  ATP-sensitive potassium channelopathies: focus on insulin secretion.

Authors:  Frances M Ashcroft
Journal:  J Clin Invest       Date:  2005-08       Impact factor: 14.808

Review 3.  Cardiac KATP channels in health and disease.

Authors:  Garvan C Kane; Xiao-Ke Liu; Satsuki Yamada; Timothy M Olson; Andre Terzic
Journal:  J Mol Cell Cardiol       Date:  2005-04-25       Impact factor: 5.000

Review 4.  K(ATP) channel therapeutics at the bedside.

Authors:  A Jahangir; Andre Terzic
Journal:  J Mol Cell Cardiol       Date:  2005-07       Impact factor: 5.000

5.  From congenital hyperinsulinism to diabetes mellitus: the role of pancreatic beta-cell KATP channels.

Authors:  Khalid Hussain; Karen E Cosgrove
Journal:  Pediatr Diabetes       Date:  2005-06       Impact factor: 4.866

6.  Functional effects of mutations at F35 in the NH2-terminus of Kir6.2 (KCNJ11), causing neonatal diabetes, and response to sulfonylurea therapy.

Authors:  Peter Proks; Christophe Girard; Halvor Baevre; Pål R Njølstad; Frances M Ashcroft
Journal:  Diabetes       Date:  2006-06       Impact factor: 9.461

Review 7.  Genetics of neonatal hyperinsulinism.

Authors:  B Glaser; P Thornton; T Otonkoski; C Junien
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2000-03       Impact factor: 5.747

8.  Elimination of allosteric modulation of myocardial KATP channels by ATP and protons in two Kir6.2 polymorphisms found in sudden cardiac death.

Authors:  Ningren Cui; Li Li; Xueren Wang; Yun Shi; Weiwei Shi; Chun Jiang
Journal:  Physiol Genomics       Date:  2006-01-10       Impact factor: 3.107

Review 9.  Pharmacogenomics and individualized drug therapy.

Authors:  Michel Eichelbaum; Magnus Ingelman-Sundberg; William E Evans
Journal:  Annu Rev Med       Date:  2006       Impact factor: 13.739

10.  A heterozygous activating mutation in the sulphonylurea receptor SUR1 (ABCC8) causes neonatal diabetes.

Authors:  Peter Proks; Amanda L Arnold; Jan Bruining; Christophe Girard; Sarah E Flanagan; Brian Larkin; Kevin Colclough; Andrew T Hattersley; Frances M Ashcroft; Sian Ellard
Journal:  Hum Mol Genet       Date:  2006-04-13       Impact factor: 6.150
View more
  17 in total

1.  Targeted disruption of K(ATP) channels aggravates cardiac toxicity in cocaine abuse.

Authors:  Santiago Reyes; Garvan C Kane; Leonid V Zingman; Satsuki Yamada; Andre Terzic
Journal:  Clin Transl Sci       Date:  2009-10       Impact factor: 4.689

Review 2.  Pharmacogenetics of Potassium Channel Blockers.

Authors:  Dan M Roden
Journal:  Card Electrophysiol Clin       Date:  2016-06

Review 3.  Small-molecule modulators of inward rectifier K+ channels: recent advances and future possibilities.

Authors:  Gautam Bhave; Daniel Lonergan; Brian A Chauder; Jerod S Denton
Journal:  Future Med Chem       Date:  2010-05       Impact factor: 3.808

Review 4.  Individualized therapy for type 2 diabetes: clinical implications of pharmacogenetic data.

Authors:  Gaia Chiara Mannino; Giorgio Sesti
Journal:  Mol Diagn Ther       Date:  2012-10       Impact factor: 4.074

Review 5.  Sulfonylurea pharmacogenomics in Type 2 diabetes: the influence of drug target and diabetes risk polymorphisms.

Authors:  Christina L Aquilante
Journal:  Expert Rev Cardiovasc Ther       Date:  2010-03

Review 6.  Molecular biology of K(ATP) channels and implications for health and disease.

Authors:  Alejandro Akrouh; S Eliza Halcomb; Colin G Nichols; Monica Sala-Rabanal
Journal:  IUBMB Life       Date:  2009-10       Impact factor: 3.885

7.  ATP-sensitive K+ channel knockout induces cardiac proteome remodeling predictive of heart disease susceptibility.

Authors:  D Kent Arrell; Jelena Zlatkovic; Garvan C Kane; Satsuki Yamada; Andre Terzic
Journal:  J Proteome Res       Date:  2009-10       Impact factor: 4.466

8.  KATP channel Kir6.2 E23K variant overrepresented in human heart failure is associated with impaired exercise stress response.

Authors:  Santiago Reyes; Sungjo Park; Bruce D Johnson; Andre Terzic; Timothy M Olson
Journal:  Hum Genet       Date:  2009-12       Impact factor: 4.132

9.  KCNJ11 knockout morula re-engineered by stem cell diploid aggregation.

Authors:  Timothy J Nelson; Almudena Martinez-Fernandez; Andre Terzic
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2009-01-27       Impact factor: 6.237

Review 10.  Human K(ATP) channelopathies: diseases of metabolic homeostasis.

Authors:  Timothy M Olson; Andre Terzic
Journal:  Pflugers Arch       Date:  2009-12-24       Impact factor: 3.657
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.